The purpose of this study is to test what effects (good and bad) a new cancer vaccine will
have on participants and their cancer, when administered before and after their autologous
hematopoietic cell transplant (HCT).
The name of the vaccine is called Dendritic Cell Survivin Vaccine (DC:AdmS). The vaccine is
made using the participant's own blood cells. The vaccine will contain a virus called an
adenovirus, similar the virus that causes the common cold. The virus has been changed so it
cannot infect humans and cause infections. The vaccine will be prepared at Moffitt Cancer
Center in the Cell Therapy Laboratory Facility.
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute